AR101389A1 - Composición que contiene apomorfina y un catión de metal divalente - Google Patents

Composición que contiene apomorfina y un catión de metal divalente

Info

Publication number
AR101389A1
AR101389A1 ARP150102457A ARP150102457A AR101389A1 AR 101389 A1 AR101389 A1 AR 101389A1 AR P150102457 A ARP150102457 A AR P150102457A AR P150102457 A ARP150102457 A AR P150102457A AR 101389 A1 AR101389 A1 AR 101389A1
Authority
AR
Argentina
Prior art keywords
metal cation
divalent metal
composition containing
composition
apomorphine
Prior art date
Application number
ARP150102457A
Other languages
English (en)
Inventor
Philip Leader Ian
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51265458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR101389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of AR101389A1 publication Critical patent/AR101389A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición que comprende apomorfina y un catión de metal divalente en una relación molar de 2 o menos, un proceso para preparar la composición, una composición obtenible mediante dicho proceso, y el uso de las composiciones como medicamento, en particular para tratar la enfermedad de Parkinson. Reivindicación 7: Composición de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composición contiene apomorfina y Ca²⁺ y Mg²⁺ los cuales están presentes en una relación de 1,37:1 a 1,72:1, preferiblemente 1,545:1. Reivindicación 8: Composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde está presente un antioxidante.
ARP150102457A 2014-08-01 2015-07-31 Composición que contiene apomorfina y un catión de metal divalente AR101389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14002689.9A EP2979688A1 (en) 2014-08-01 2014-08-01 Composition containing Apomorphine and a Divalent Metal Cation

Publications (1)

Publication Number Publication Date
AR101389A1 true AR101389A1 (es) 2016-12-14

Family

ID=51265458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102457A AR101389A1 (es) 2014-08-01 2015-07-31 Composición que contiene apomorfina y un catión de metal divalente

Country Status (14)

Country Link
US (1) US11419863B2 (es)
EP (2) EP2979688A1 (es)
JP (1) JP6760923B2 (es)
KR (1) KR102485809B1 (es)
AR (1) AR101389A1 (es)
AU (1) AU2015295817C1 (es)
CA (1) CA2954223C (es)
DK (1) DK3174526T4 (es)
ES (1) ES2757060T5 (es)
FI (1) FI3174526T4 (es)
MY (1) MY180540A (es)
SG (2) SG10201900892SA (es)
TW (1) TW201605448A (es)
WO (1) WO2016015875A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CA2772878A1 (en) * 2009-09-01 2011-03-10 Lz Therapeutics, Inc. Ganglioside transmucosal formulations
US20110111101A1 (en) 2009-11-06 2011-05-12 Graham Packaging Company, L.P. Method and apparatus of packaging beverage mixture
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
MX2014014902A (es) * 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
MA43042A (fr) 2015-09-28 2018-08-08 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanée

Also Published As

Publication number Publication date
US20170136002A1 (en) 2017-05-18
JP6760923B2 (ja) 2020-09-23
SG10201900892SA (en) 2019-02-27
EP3174526A1 (en) 2017-06-07
KR20170068435A (ko) 2017-06-19
EP3174526B2 (en) 2023-03-22
JP2017522358A (ja) 2017-08-10
KR102485809B1 (ko) 2023-01-05
AU2015295817A1 (en) 2017-02-16
WO2016015875A1 (en) 2016-02-04
CA2954223A1 (en) 2016-02-04
AU2015295817C1 (en) 2022-11-17
AU2015295817B2 (en) 2020-04-02
DK3174526T4 (da) 2023-04-24
ES2757060T3 (es) 2020-04-28
MY180540A (en) 2020-12-01
CA2954223C (en) 2022-05-10
EP2979688A1 (en) 2016-02-03
US11419863B2 (en) 2022-08-23
SG11201700098YA (en) 2017-02-27
EP3174526B1 (en) 2019-09-11
DK3174526T3 (da) 2019-10-07
FI3174526T4 (fi) 2023-08-31
TW201605448A (zh) 2016-02-16
ES2757060T5 (es) 2023-08-21

Similar Documents

Publication Publication Date Title
CL2017002650A1 (es) Compuestos novedosos
CO2017001884A2 (es) Polimorfos de selinexor
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CR20160433A (es) Nuevos compuestos
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CO2017003798A2 (es) Método de tratamiento para antibrote de tubérculos con cantidad reducida de cipc
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio
ECSP19026563A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
CR20150641U (es) Composiciones farmacéuticas
AR101389A1 (es) Composición que contiene apomorfina y un catión de metal divalente
BR112017003916A2 (pt) Processo para preparar derivados de 3- fenil/heteroaril-6-fenóxi-8-alquilamino-imidazo [1,2 -b]piridazina
MA39762A (fr) Nouveaux composés

Legal Events

Date Code Title Description
FB Suspension of granting procedure